Secretary
Dr. Ward founded the Collaborative Trajectory Analysis Project (cTAP), a pan-stakeholder alliance applying advanced data science to the largest collection of patient clinical data in Duchenne Muscular Dystrophy. A pharmaceutical executive, scientist, consultant, and educator, she was a leading pain researcher before joining Wyeth (now Pfizer), where she became the first woman in the industry to head R&D in the U.K., pioneering project management in drug discovery and contributing to the development and global approval of Enbrel, Rapamune, and the first toxin-antibody conjugates in cancer. As an officer of Millennium Pharmaceuticals (now Takeda), she led strategy, productivity, and technology platforms, later advising Alnylam, Novartis, and other innovative companies. Finally, Dr. Ward is a member of the External Advisory Board for the Patient Lifestyle and Disease Data Interactium (PaLaDIn) Project, a multi-stakeholder collaboration led by TREAT-NMD that aims to accelerate research, understanding and treatment for neuromuscular and other rare diseases. Dr. Ward is a member of the MGH-Harvard Rare Disease Think Tank, an independent biotech board director, and former Trustee and Finance Chair of the Cambridge School of Weston. She holds a Ph.D. from the University of Manchester, has authored over 60 peer-reviewed articles, and holds 9 patents.
